Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960516 | 1.00 | ADRB2 (0.50) | ADRB2APPPSEN1PSEN2APH1B | |
| SCHEMBL30688937 | 1.00 | ADRB2 (0.50) | ADRB2APPPSEN1PSEN2APH1B | |
| SCHEMBL957890 | 1.00 | ADRB2 (0.50) | ADRB2APPPSEN1PSEN2APH1B | |
| SCHEMBL29809135 | 1.00 | ADRB2 (0.50) | ADRB2APPPSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL25385811 | 0.98 | ADRB2 (0.48) | ADRB2APPPSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL31123022 | 0.98 | ADRB2 (0.48) | ADRB2APPPSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL25385814 | 0.98 | ADRB2 (0.48) | ADRB2APPPSEN1PSEN2APH1B | |
| SCHEMBL1556537 | 0.84 | APP (0.39) | ADRB2APPPSEN1PSEN2APH1B | |
| SCHEMBL21817525 | 0.83 | ADRB2 (0.56) | ADRB2APPLMNATP53HTT | |
| SCHEMBL643037 | 0.83 | ADRB2 (0.56) | ADRB2APPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| CN-117229210-A | Decahydroisoquinoline compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-114835687-B | AhR inhibitors | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-114835687-A | AhR inhibitors | 重庆华森制药股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-2787992-B1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016095088-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9073853-B2 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | SANOFI (FR) | 2015-07-07 | — | — | US | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20140288106-A1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| CN-1332725-A | Thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-01-23 | — | — | CN | disclosed |
| US-6335350-B1 | VARICELLA-ZOSTER, HUMAN CYTOMEGALO, EPSTEIN-BARR AND KAPOSI HERPESVIRUS TREATMENT | AMERICAN HOME PRODUCTS CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6271236-B1 | PHENYL UREAS/THIOUREAS AS INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE ENZYME, USEFUL IN TREATING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, AND VARICELLA-ZOSTER VIRUS | WYETH | 2001-08-07 | — | — | US | disclosed |
| US-6262082-B1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | WYETH | 2001-07-17 | — | — | US | disclosed |
| US-6262090-B1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6207715-B1 | USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288106-A1 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CCR5 | ADRB2 623/4885APP 2168/4885PSEN1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.